A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure

New England Journal of Medicine

Volumn 339, Issue 25, 1998, Pages 1810-1816

  Cohn, Jay N ^a   Goldstein, Sidney O ^b   Greenberg, Barry H ^c   Lorell, Beverly H ^d   Bourge, Robert C ^e   Jaski, Brian E ^f   Gottlieb, Sidney O ^g   Mcgrew III, Frank ^h   Demets, David L ⁱ   White, Bill G ^j  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c UCSD MEDICAL CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e University of Alabama at Birmingham   (United States)

^f San Diego Cardiac Center   (United States)

^g UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^h The Stern Cardiovascular Center   (United States)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^j Clinical Cardiovascular Research   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INOTROPIC AGENT; PIPERANOMETOZINE; PLACEBO;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; SURVIVAL RATE;

AGED; AGRANULOCYTOSIS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARRHYTHMIA; CARDIOTONIC AGENTS; DEATH, SUDDEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUINOLINES; SURVIVAL ANALYSIS;

EID: 0032542385     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199812173392503     Document Type: Article

References (21)

1. Taira N, Endoh M, Iijima T, et al. Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzl)-1-piperazinyl]-2(1H)-quinolone (OPC-8212), a novel positive inotropic drug, on the dog heart. Arzneimittelforschung 1984;34:347-55.
2. Yatani A, Imoto Y, Schwartz A, Brown AM. New positive inotropic agent OPC-8212 modulates single Ca2+ channels in ventricular myocytes of guinea pig. J Cardiovasc Pharmacol 1989;13:812-9.
3. Cavusoglu E, Frishman WH, Klapholz M. Vesnarinone: a new inotropic agent for treating congestive heart failure. J Card Fail 1995;1:249-57.
4. Sasayama S, Inoue M, Asanoi H, et al. Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure. Heart Vessels 1986;2:23-8.
5. Asanoi H, Sasayama S, Iuchi K, Kameyama T. Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure. J Am Coll Cardiol 1987;9:865-71.
6. Kubo SH, Rector TS, Strobeck JE, Cohn JN. OPC-8212 in the treatment of congestive heart failure: results of a pilot study. Cardiovasc Drugs Ther 1988;2:653-60.
7. Asanoi H, Sasayama S, Kameyama T, Ishizaka S, Iuchi K. Sustained inotropic effects of a new cardiotonic agent: OPC-8212 in patients with chronic heart failure. Clin Cardiol 1989;12:133-8.
8. Feldman AM, Beckcr LC, Llewellyn MP, Baughman KL. Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure. Am Heart J 1988;116:771-7.
9. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-55.
10. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1993;71:1106-7.
11. Cohn JN. The management of chronic heart failure. N Engl J Med 1996;335:490-8.
12. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6. [Erratum, Lancet 1990;336: 698.]
13. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
14. Just H, Hjalmarsson A, Remme WJ, et al. Pimobendan in congestive heart failure: results of the PICO Trial. Circulation 1995;92:Suppl I:I-722. abstract.
15. Lathrop DA, Schwartz A. Evidence for possible increase of sodium channel open time and involvement of Na/Ca exchange by a new positive inotropic drug: OPC-8212. Eur J Pharmacol 1985;117:391-2.
16. Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinon on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation 1993;88:Suppl I:I-301. abstract.
17. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation 1993;87:Suppl VI:VI-17-VI-23.
18. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
19. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994;89:955-8.
20. Rector TS, Tschumperlin LK, Kubo SH, et al. Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. J Card Fail 1995; 1:201-6.
21. Cohn JN. Intent-to-treat: a curse of clinical trials. J Card Fail 1998;4:1-2.